ABSTRACT
No data are available for the kinetics of anti-Hepatitis C Virus (HCV) antibodies in HIV/HCV co-infected patients after sustained virological response (SVR). We present a case of a HIV/HCV co-infected patient, showing a significant anti-HCV antibodies decrease during therapy, who achieved a HCV seroreversion 3 years after SVR. Among them, antibodies to core protein, the most strongly antigenic protein showed significant decrease. Our results indicate an absence of antigenic stimulation suggesting a total clearance of HCV.
Subject(s)
HIV Infections/virology , Hepatitis C Antibodies/blood , Hepatitis C/immunology , Hepatitis C/virology , Adult , Antiviral Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/immunology , Hepatitis C/drug therapy , Humans , Male , Treatment Outcome , Viral LoadABSTRACT
OBJECTIVES: The aims of the study were to assess in patients with advanced HIV disease receiving antiretroviral therapy (ART) intensification with enfuvirtide (i) resistance at virological failure (VF), (ii) impact of baseline tropism on immunovirological response, and (iii) HIV-1 DNA tropism evolution during ART. METHODS: The ANRS 130 APOLLO randomized trial evaluated in naive patients the immunovirological impact of standard ART without (control arm) or with enfuvirtide. Tropism was determined on RNA and DNA by V3-loop sequencing interpreted using the Geno2Pheno algorithm. RESULTS: At baseline the median CD4 cell count was 30 cells/mm(3). Among the 170 patients assessable in this virological substudy, HIV-1 RNA tropism was as follows: 60% of viruses were R5 and 40% were R5X4/X4. HIV-1 DNA tropism was as follows: 54% were R5 and 46% were R5X4/X4. At week 24, 39% and 49% of patients experienced VF in the enfuvirtide and control arms, respectively. In the enfuvirtide arm, only resistance-associated mutations to enfuvirtide were detected. In the control arm, two patients displayed drug-resistant viruses at the time of VF. No impact of baseline tropism was observed on immunovirological response, regardless of the study arm. Among the 25 patients experiencing DNA tropism switch between baseline and week 24, 16 (64%) switched from R5 to R5X4/X4. These latter were mostly successfully suppressed patients receiving enfuvirtide and exhibiting poorer immunological response. CONCLUSIONS: Baseline RNA tropism had no impact on the immunovirological response. Drug resistance mutations were only detected for the fusion inhibitor. Finally, the mechanism of replenishment of the viral cellular reservoir with X4 viruses observed needs to be further analysed.
Subject(s)
Anti-HIV Agents/administration & dosage , Evolution, Molecular , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/genetics , HIV-1/pathogenicity , Viral Tropism , Adolescent , Adult , Aged , Antiretroviral Therapy, Highly Active/methods , Drug Resistance, Viral , Enfuvirtide , HIV Envelope Protein gp41/administration & dosage , Humans , Middle Aged , Mutation, Missense , Peptide Fragments/administration & dosage , Young AdultABSTRACT
BACKGROUND: The number of international trips undertaken by French citizens is rising and we wished to assess the appropriateness of advices given to travelers in a vaccine and travel medicine center in France. METHODS: We conducted a 3-month prospective study in one center in Paris where prescriptions and advice to travelers are given by trained physicians in travel medicine who have access to a computerized decision support system (Edisan). A questionnaire was used to record trip characteristics, patients' demographics, and prescriptions. Main outcome measure was the adequacy of prescriptions for malaria prophylaxis, yellow fever, and hepatitis A vaccines to French guidelines. RESULTS: A total of 730 subjects were enrolled in this study, with a median age of 28 years. Travel destinations were sub-Saharan Africa (58%), Asia (21%), and South America (18%). Among the 608 patients (83%) traveling to malaria-endemic areas, malaria prophylaxis was in accordance with guidelines in 578/608 patients (95.1%, 95% CI: 93-96.5), and doxycycline was the regimen of choice (48%). Inappropriate malaria prophylaxis was given to eight patients, one of whom developed plasmodium falciparum malaria. All 413 patients (100%, 95% CI: 99-100) traveling to yellow fever-endemic areas who needed vaccination were correctly vaccinated. However, three patients received yellow fever vaccination without indication. Also, 442 of 454 patients (97.4%, 95% CI: 95.4-98.5) eligible to receive hepatitis A vaccination were immunized. CONCLUSION: Appropriate advice for malaria prophylaxis, yellow fever, and hepatitis A vaccinations was provided in a travel medicine and vaccine center where trained physicians used a computerized decision support system. Even in this setting, however, errors can occur and professional practices should be regularly assessed to improve health care.
Subject(s)
Endemic Diseases/prevention & control , Hepatitis A , Malaria , Practice Patterns, Physicians' , Travel , Vaccination , Yellow Fever , Adult , Africa South of the Sahara/epidemiology , Ambulatory Care Facilities/standards , Ambulatory Care Facilities/statistics & numerical data , Antimalarials/therapeutic use , Asia/epidemiology , Consultants/statistics & numerical data , Decision Making, Computer-Assisted , Female , Guideline Adherence/statistics & numerical data , Hepatitis A/epidemiology , Hepatitis A/prevention & control , Humans , Malaria/epidemiology , Malaria/prevention & control , Male , Outcome Assessment, Health Care , Paris , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/statistics & numerical data , Prospective Studies , Quality of Health Care , South America/epidemiology , Surveys and Questionnaires , Travel Medicine/methods , Vaccination/methods , Vaccination/statistics & numerical data , Vaccines/therapeutic use , Yellow Fever/epidemiology , Yellow Fever/prevention & controlABSTRACT
Clinical, biological, and radiological findings of influenza A (H1N1)-confirmed cases among HIV-infected patients presenting in a French university hospital between October 2009 and January 2010 were systematically reviewed. No severe influenza infection was observed, but a high frequency of secondary bacterial pneumonia is reported among pneumococcal unvaccinated patients.
Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human , Adult , Coinfection , France , HIV Infections , HumansABSTRACT
OBJECTIVES: To evaluate the efficacy of adding interleukin-2 (IL-2) to an optimized background treatment in HIV-1 patients with advanced failure. DESIGN: Randomized, open-label, multicentre controlled trial. METHODS: Patients with CD4 T-cell count of less than 200 cells/microl, plasma HIV-1 RNA of more than 10 000 copies/ml and a genotypic sensitivity score showing two or less active drugs were randomized to either eight IL-2 cycles with optimized background treatment or optimized background treatment alone. Optimization was made according to genotypic sensitivity score. Enfuvirtide was added in enfuvirtide-naive patients. Evaluation was performed at week 52 on the proportions of patients with CD4 cell count of at least 200 cells/microl (primary outcome), of patients with a CD4 cell count increase of at least 50 cells/microl from week 0, on plasma HIV-1 RNA and HIV-related events. RESULTS: Fifty-six patients were analysed. Median age was 43 years, 61% were at Center for Disease Control and Prevention stage C, 43% had a genotypic sensitivity score of 0, median baseline CD4 cell count and plasma HIV-1 RNA values were 64 cells/microl and 4.9 log10 copies/ml, respectively. Treatment could be optimized in 23 patients. At week 52, in the IL-2 and control groups, the proportion of patients with CD4 cell count of at least 200 cells/microl (14 and 18%) or a CD4 cell count increase of at least 50 cells/microl (25 and 32%) and median plasma HIV-1 RNA were not significantly different. In multivariate analysis, optimization with enfuvirtide and baseline CD4 cell count were statistically associated with CD4 cell count of at least 200 cells/microl at week 52 (P = 0.003 and P = 0.01). Optimization with enfuvirtide was the only factor associated with a CD4 cell count gain of at least 50 cells/microl (P < 0.001). There was no difference in the rate of AIDS events between groups. CONCLUSION: IL-2 failed to increase CD4 cell count in immunocompromised patients with multiple therapeutic failures. Enfuvirtide use was highly associated with success.